<code id='A1C2A4DCB7'></code><style id='A1C2A4DCB7'></style>
    • <acronym id='A1C2A4DCB7'></acronym>
      <center id='A1C2A4DCB7'><center id='A1C2A4DCB7'><tfoot id='A1C2A4DCB7'></tfoot></center><abbr id='A1C2A4DCB7'><dir id='A1C2A4DCB7'><tfoot id='A1C2A4DCB7'></tfoot><noframes id='A1C2A4DCB7'>

    • <optgroup id='A1C2A4DCB7'><strike id='A1C2A4DCB7'><sup id='A1C2A4DCB7'></sup></strike><code id='A1C2A4DCB7'></code></optgroup>
        1. <b id='A1C2A4DCB7'><label id='A1C2A4DCB7'><select id='A1C2A4DCB7'><dt id='A1C2A4DCB7'><span id='A1C2A4DCB7'></span></dt></select></label></b><u id='A1C2A4DCB7'></u>
          <i id='A1C2A4DCB7'><strike id='A1C2A4DCB7'><tt id='A1C2A4DCB7'><pre id='A1C2A4DCB7'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:331
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Why does health care cost so much? A reading guide
          Why does health care cost so much? A reading guide

          MikeReddyforSTATYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofm

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Medicare will require more price transparency from hospitals

          Medicarewillforcehospitalstobebetteraboutpublishingthepricestheychargehealthinsurersandpatients.DonP